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Background/aim: Neurofilaments are intermediary filaments associated with neurodegenerative processes. Thrombospondin-1 (TSP1) is a biological marker playing a role in synaptogenesis. This study aimed to investigate serum neurofilament light chain (NFL), and
TSP1 levels of patients with autism spectrum disorder (ASD) compared to typically developing (TD) children.
Materials and methods: Forty-three patients with ASD and forty-five TD children were included. Serum biomarker levels were
measured using the sandwich ELISA technique. The Childhood Autism Rating Scale (CARS) was implemented to measure the severity
of ASD.
Results: NFL and TSP1 levels did not differ between study groups (For NFL, ASD = 47.8 ± 11.4 vs. TD = 48.2 ± 15.3 pg/mL, p = 0.785;
for TSP1, ASD = 224.4 ± 53.7 vs. TD = 224.7 ± 69.0 ng/mL, p = 0.828). Stereotyped behavior and sensory sensitivity domain of the CARS
scale was negatively correlated with serum TSP-1 (r = –0.390, p = 0.010) and NFL (r = –0.377, p = 0.013) levels. Age was also positively
correlated with NFL levels (r = 0.332, p = 0.030) in the ASD groups but not in the TD group.
Conclusion: Our results did not support the neurodegenerative process of ASD. Future studies are needed to investigate neuroprogression
in a longitudinal follow-up.
Key words: Neurofilament light chain, thrombospondin, autism, neurodegeneration

1. Introduction
Autism spectrum disorder (ASD) is a neurodevelopmental
disorder characterized by deficits in social interaction,
verbal and nonverbal communication, as well as
restricted, repetitive patterns of behaviors and interests
[1]. The underlying genetic etiology of ASD has been
previously investigated, and many genes associated with
neurogenesis, brain maturation, and synaptogenesis have
been implicated in the pathophysiology of the disorder
[2–4]. Neurodegenerative processes and immune system
abnormalities have been proposed in the etiology of ASD
[5,6]. Neuronal cell loss, microglia, and astrocyte activation
increased proinflammatory cytokines, and oxidative
stress might play a role in ASD, indicating the possible
role of neurodegenerative processes [6,7]. Additionally,
lymphocyte/monocyte ratio, platelet/lymphocyte ratio
(PLR), and neutrophil/lymphocyte ratio (NLR) were
examined as the peripheral biomarkers of inflammation,
which could be rapidly obtained from routine blood tests

[8,9]. Especially, NLR was proposed as a cost-effective
measurement, which might have clinical implications
[9]. However, these findings in the previous literature
were limited. Despite being widely investigated, there is
no established biomarker that reflects changes during
the illness course [10]. ASD may involve some processes
that occur in neurodegeneration; therefore, finding a
biomarker remained a research endeavor to monitor
clinical deterioration and prognosis.
Neurofilaments were structural elements of the
cytoskeleton, composed of four subunits neurofilament
light chain (NFL), neurofilament medium-chain (NF-M),
neurofilament heavy chain (NF-H), and alpha-internexine
or peripherin [11]. NFL was widely expressed in myelinated
subcortical axons of the central nervous system (CNS)
[12,13]. Previous studies demonstrated the structural and
functional role of neurofilaments in synaptic junctions
[13]. Also, neurofilaments were associated with axonal
injury and traumatic brain damage [12–14].
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In the previous literature, a recent study demonstrated
that cerebrospinal fluid (CSF) and serum NFL could be a
biomarker of neurodegeneration in mice [15]. Increased
NFL in CSF was also associated with several neurologic
conditions, including Alzheimer’s disease, amyotrophic
lateral sclerosis, multiple sclerosis, inherited neuropathy,
Parkinson’s disease, dementia, multiple system atrophy,
and progressive supranuclear palsy, also predicting the
prognosis of Alzheimer’s and Parkinson’s diseases [16–19].
Additionally, previous research revealed the association
between sports-related repetitive head trauma and
increased NFL within CSF, supporting the notion that the
NFL might indicate chronic traumatic brain injury [14].
Neurofilaments could be reliably measured in CSF. Also,
there was a significant association between serum and
CSF neurofilament levels [20]. Accordingly, another study
showed the correlation between plasma and CSF levels in
patients with amyotrophic lateral sclerosis and blood NFL
was nearly four times higher in the patient group than
healthy controls, which also increases the risk of mortality
as a prognostic biomarker [19]. In addition, recently, He
and colleagues [21] revealed that serum NFL levels of
patients with ASD were higher than typically developed
(TD) children.
Thrombospondins (TSP) are matricellular regulator
proteins that are dynamically expressed within the
extracellular matrix (ECM) and implicated in the
pathogenesis of several neurological illnesses [22]. TSP1, initially considered a regulator protein of angiogenesis,
plays several key roles in the angiogenic function, including
apoptosis, cell-cell interaction, adhesion, and migration
[22,23]. Besides, astrocytes were discovered to express
TSP-1, which mediates synaptogenesis by interacting
with neuroligin 1 in hippocampal neurons [22,24]. Given
the synapse-modulating role of neuroligins, it has been
proposed that there might be a possible link between
secreted synapse-modulating glial proteins and impaired
synaptic connectivity in ASD [25]. Furthermore, another
study also suggested common variants of the THBS1
gene, encoding thrombospondin 1 protein, could be
protective against autism and rare variants pose a genetic
predisposition to autism [26]. However, these results were
not conclusive for the relationship between TSP-1 and
autism since more studies are still needed to extend the
clinical implications of previous findings.
Considering the increasing body of evidence for the
use of NFL in neurologic and psychiatric conditions in
the previous literature, we aimed to evaluate serum NFL
levels of peripubertal patients with ASD compared to TD
children. Likewise, given the potential role of TSP-1 in
synaptogenesis, these novel biomarker candidates should
be explored in ASD. To this end, we investigated serum
NFL and TSP-1 levels in patients with ASD compared to
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typically developing children. We hypothesized children
with ASD would yield higher levels of peripheral NFL and
TSP-1 due to neuronal loss and synaptic disintegration.
Second, we expected the severity and age were positively
correlated with both peripheral biomarkers among the ASD
group, indicating an inflammatory and neurodegenerative
process in the course of autism. Finally, PLR and NLR were
compared between patients with ASD and TD controls.
2. Method
2.1. Participants
Forty-three patients with ASD and 45 TD children were
included in the study between May 2018–May 2020.
Patients with ASD were registered and regularly followed
children in the outpatient clinic of a tertiary-care university
hospital. All clinical diagnoses were confirmed by an
experienced clinician in neurodevelopmental disorders
as per the Diagnostic and Statistical Manual of Mental
Disorders-5 [1]. TD group, recruited from the pediatric
outpatient clinic, consisted of healthy children who had
similar age and sex characteristics. The healthy controls
were examined for neurologic and psychiatric disorders.
Subjects who had i) psychiatric disorders, ii) neurologic
illnesses, and iii) any delay in developmental milestones
were not included. Sociodemographic and illness
characteristics were obtained from caregivers, and the
severity of illness was measured using the Turkish version
of the Childhood Autism Rating Scale (CARS) [27].
Inclusion criteria involved (i) being aged between 6–18
years and (ii) the total score of CARS ≥ 30 for the subjects
with ASD. Patients with (i) genetic, neurodegenerative,
inflammatory, autoimmune, and neoplastic diseases; (ii)
the history of traumatic brain injury, (iii) the presence
of ischemic brain illness, fever, renal or hepatic failure,
recent or acute infection and (iv) the presence of mood
disorders and psychotic disorders were excluded from the
study. Informed consent was obtained from all parents and
typically developing children. The patients were enrolled
after obtaining written informed consent or assent
(whenever applicable). The Local Ethical Committee of
Dokuz Eylül University reviewed and approved the study
protocol (number: 441-SBKAEK).
2.2. Procedures
Serum NFL and TSP-1 levels were measured with a
commercial kit for sandwich Enzyme-Linked immune
sorbent assay (For NFL, catalog number: YLA4279HU,
assay range = 1.56–300 pg/mL, sensitivity = 0.54 pg/
mL, CV: intra-assay < 10%, inter-assay < 12%; for TSP-1,
catalog number: YLA1727HU, assay range = 5–700 ng/mL,
sensitivity = 2.39 ng/mL, CV: intra-assay < 8%, inter-assay
< 10%, Shangai YL Biotech Co.). Additional information
was obtained from electronic patient files or treating
physicians. Total blood count was also implemented. PLR
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and NLR parameters were calculated from total blood
count results. Electroencephalography (EEG) at sleep
states was recorded using scalp electrodes per International
10/20 system using a 16-channel EEG system for 30
min (EEG-9200K, Nihon Kohden Corporation, Tokyo).
All records were evaluated by two pediatric neurology
consultants independently. Findings were classified as (i)
normal EEG, (ii) abnormal background activity, and (iii)
epileptic abnormalities. When patients were compliant
with procedures, Magnetic Resonance Imaging (MRI) at
1.5 T was implemented.
2.3. Statistical analysis
Power analysis (power = 0.90, alpha = 0.05) based on the
previous research indicated 40 participants in each group
[21]. The three-factor model of the CARS scale was used
to measure the severity of (i) social communication, (ii)
emotional reactivity, and (iii) stereotyped behavior and
sensorial sensitivity subdomains of ASD [28].
Categorical variables were represented as
frequencies and compared by using the chi-square test.
Continuous variables were demonstrated as means and
standard deviations. Normal distribution of continuous
variables was controlled using skewness and kurtosis
values. The independent-sample t-test was used to
compare continuous demographic variables. Pearson
correlation was also calculated to test the relationship
between blood biomarkers and the characteristics of
participants.
After subdividing participants into two different age
categories (adolescents aged ≥ 12 years and children
less than 12 years), we have implemented posthoc twoway ANOVA models using two categorical variables (i.e.
diagnostic category and age category). The assumption for
homogeneity of variances was tested using Levene’s test. In
these two-way ANOVA models, diagnoses (i.e. ASD or TD
controls) and age categories (i.e. children and adolescents)
were variables to test their effect on serum NFL and TSP-1
levels.
Finally, posthoc subgroup analyses were conducted to
compare patients receiving medications and those with
MRI or EEG abnormalities by using the Mann-Whitney
U test due to the sample size. Alpha was set at 0.05 twotailed for statistical significance. All statistical analyses
were performed in the SPSS software version 24.0 (IBM
Corporation, Armonk, NY, USA).
3. Results
3.1. Demographic and illness characteristics
Table 1 demonstrates the sociodemographic and
clinical characteristics of study participants. ASD and
TD groups did not show any statistically significant
difference for age and sex characteristics. In the ASD
group, the mean age at the time of diagnosis was 3.3

± 1.1 years. MRI scans (17.9%) and EEG examinations
(24.3%) revealed abnormal findings among patients
with autism. The total score of CARS was 41.7 ± 5.2 for
the patient group.
3.2. Serum biomarker levels and blood count results of
study participants
Blood count results and serum biomarker levels of study
groups are shown in Table 2. The ASD group had a higher
number of lymphocytes compared to the comparison
group. The number of neutrophils and platelets was similar
between the study groups. PLR was also significantly lower
in the ASD group. Serum TSP-1 and NFL levels did not
differ between study groups. In two-way ANOVA models
including diagnosis (i.e. ASD or TD controls) and the
age category (i.e. children or adolescents), there was also
no significant effect of diagnosis (F = 0.1, p = 0.785), age
category (F = 2.4, p = 0.124) or the interaction between
both variables (F = 0.2, p = 0.625) on serum NFL levels.
Likewise, diagnostic category (F = 0.0, p = 0.828), the
age group (F = 2.3, p = 0.135) and the interaction effect
(F = 0.0, p = 0.862) were not significant in the models to
estimate serum TSP-1.
3.3. Correlation analysis between serum biomarkers,
age, and the illness severity
The total CARS score was not statistically correlated
with serum NFL and TSP levels (Table 3). The total score
of stereotyped behavior and sensorial sensitivity was
negatively correlated with serum NFL and TSP-1. Total
social communication and emotional reactivity scores
were not associated with NFL and TSP-1 levels. In the
ASD group, age was positively correlated with serum NFL
(r = 0.332, p = 0.030) and the correlation between age and
TSP-1 was at trend level (r = 0.283, p = 0.066). In contrast,
age did not show any significant correlation with NFL and
TSP-1 in TD comparisons (For NFL, r = 0.003, p = 0.985;
for TSP-1, r = 0.067, p = 0.664).
3.4. Subgroup analysis of patient receiving antipsychotic
medications
In order to detect possible effects of medication on
outcomes of interest, we implemented post-hoc subgroups
analyses between patients receiving antipsychotic (n = 28)
and antiepileptic (n = 7) medications among patients with
ASD. Antipsychotic-user (65.1%) vs. nonuser (34.9%)
groups did not differ regarding serum TSP-1 (antipsychoticuser group = 227.1 ± 57.0 vs. 219.4 ± 48.3 ng/mL, Z = 0.5, p
= 0.637) and NFL (antipsychotic-user group = 47.7 ± 12.6
vs. 47.9 ± 9.2 pg/mL, Z = 0.8, p = 0.422). Similarly, patients
receiving antiepileptic medication (16.3%) did not differ
from nonuser group (83.7%) (For TSP-1, antiepilepticuser group = 227.1 ± 57.0 vs. 219.4 ± 48.3 ng/mL, Z = 0.5,
p = 0.637; for NFL, antiepileptic-user group = 47.7 ± 12.6
vs. 47.9 ± 9.2 pg/mL, Z = 0.8, p = 0.422).
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Table 1. Demographic and clinical characteristics of study participants.
Variables

ASD, n = 43

TD, n = 45

Statistics

p

Age, years, mean ± SD

10.0 ± 2.7

10.9 ± 3.2

t = 1.3

0.189

χ² = 1.2

0.277

Male

34 (79.1)

31 (68.9)

Female

9 (20.9)

14 (31.1)

3.3 ± 1.1

-

-

-

28 (65.1)

-

-

-

7 (16.3)

-

-

-

23 (82.1)

-

-

-

5 (17.9)

-

-

-

Normal

28 (75.7)

-

-

-

Abnormal background activity

2 (5.4)

-

-

-

Epileptic abnormalities

7 (18.9)

-

-

-

Social communication

20.7 ± 2.7

-

-

-

Emotional reactivity

8.2 ± 1.4

-

-

-

Stereotyped behavior and sensory sensitivities

10.4 ± 1.7

-

-

-

Total CARS score

41.7 ± 5.2

-

-

-

Sex, n (%)

Age at the time of diagnosis, years, mean ± SD
Medications, n (%)
Antipsychotic
Antiepileptic
MRI evaluation, n (%)

a

Normal
Abnormal findings

b

EEG assessment, n (%) c

CARS scores, mean ± SD

d

Note ASD = autism spectrum disorder, CARS = The Childhood Autism Rating Scale, EEG = electroencephalography,
MRI = magnetic resonance imaging, SD = standard deviation, TD = typically developing children.
a
This variable was available for 28 cases.
b
Abnormal MRI findings involved periventricular leukomalacia (n = 2), cortical dysplasia (n = 1), and cerebral atrophy
(n = 2).
c
This variable was available for 37 cases.
d
One item (visual response) did not load on any factor an was only counted in the total score.

3.5. Subgroup analyses of patients with EEG and MRI
abnormalities
Serum NFL levels did not differ between patients with
normal MRI findings and those with abnormal MRI
findings (patients with normal MRI findings = 44.5 ± 6.5
vs. patients with abnormal MRI = 46.6 ± 9.3 pg/mL, Z =
0.2, p = 0.834). Similarly, TSP-1 levels were similar between
both subgroups (patients with normal MRI findings = 204.4
± 32.1 vs. 225.1 ± 41.4 ng/mL, Z = 1.1, p = 0.280). In EEG
assessments patient with abnormal background activity
(n = 2) and epileptic abnormalities (n = 7) were grouped
together to compare with those having normal EEG. Patients
with normal EEG findings had higher levels of serum NFL
compared to those with abnormal EEG findings (patients
with normal EEG findings = 45.2 ± 8.8 vs. 49.3 ± 8.0 pg/
mL, Z = 2.0, p = 0.045). Finally, TSP levels were similar in
both patient subgroups (patients with normal EEG findings
= 211.7 ± 43.5 vs. 233.3 ± 39.4 ng/mL, Z = 1.6, p = 0.111).
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4. Discussion
Our study results suggested no difference between
patients with ASD and typically developing children in
terms of serum NFL and TSP-1 levels. Age was positively
correlated with plasma NFL among patients with
autism but not in controls. Stereotyped behavior and
sensorial sensitivity scores were negatively correlated
with serum NFL and TSP-1 levels. Conversely, the total
CARS score, social communication, and emotional
domain scores did not yield any correlation with
both biomarkers. In posthoc subgroup analyses,
antipsychotic and antiepileptic medications had no
significant effect on TSP-1 and NFL. Finally, in the
blood count analysis, lymphocytes and PLR were lower
in ASD than in TD. To our knowledge, this is the first
study that examines serum TSP-1 levels of patients with
ASD in the literature.

PAKETÇİ et al. / Turk J Med Sci
Patients with ASD did not differ from the control group
regarding plasma NFL as a biomarker of neural loss. This
result was not in line with the previous study conducted by
He and colleagues [21]. The mean age of the previous study

was 5.1 years [21], which was lower than the mean age of
our sample and might partially account for the discrepancy
between the results given the significant correlation
between age and serum NFL levels. Divergent findings

Table 2. Biomarker levels and blood count results of study participants.
Variables

ASD

TD

Diagnosis

Age group

Interaction

(mean ± SD)

n = 43 a

n = 45 a

F

p

F

p

F

p

2.1

0.151

2.8

0.096

1.6

0.209

0.3

0.614

0.5

0.500

0.4

0.516

5.0

0.027

6.6

0.012

3.1

0.082

2.7

0.105

2.5

0.115

1.0

0.310

0.6

0.439

0.1

0.708

0.2

0.636

6.6

0.012

1.3

0.250

0.9

0.345

0.0

0.828

2.3

0.135

0.0

0.862

0.1

0.785

2.4

0.124

0.2

0.625

WBC (10 /µL)
3

Children

8.2 ± 2.0

7.0 ± 1.5

Adolescents

6.9 ± 2.2

6.8 ± 2.1

Total

7.9 ± 2.1

6.9 ± 1.7

Neutrophils (103/µL)
Children

4.1 ± 1.5

3.7 ± 1.4

Adolescents

3.7 ± 1.5

3.7 ± 1.4

Total

4.0 ± 1.5

3.7 ± 1.4

Lymphocytes (103/µL)
Children

3.2 ± 0.9

2.5 ± 0.6

Adolescents

2.4 ± 0.7

2.3 ± 0.7

Total

3.0 ± 0.9

2.4 ± 0.6

Children

322.6 ± 84.6

333.8 ± 55.0

Adolescents

275.6 ± 82.6

323.5 ± 71.0

Total

312.8 ± 85.4

330.6 ± 59.8

Children

1.4 ± 0.7

1.7 ± 1.2

Adolescents

1.6 ± 0.6

1.6 ± 0.5

Total

1.4 ± 0.7

1.6 ± 1.0

Children

105.5 ± 33.1

142.5 ± 42.3

Adolescents

127.7 ± 76.6

144.7 ± 35.0

Total

110.1 ± 45.4

143.2 ± 39.8

Platelets (10 /µL)
3

NLR

PLR

TSP1 (ng/mL)
Children

219.0 ± 45.2

218.3 ± 67.6

Adolescents

244.8 ± 78.3

238.8 ± 72.4

Total

224.4 ± 53.7

224.7 ± 69.0

NFL (pg/mL)
Children

46.4 ± 9.6

47.1 ± 13.8

Adolescents

53.2 ± 16.2

50.6 ± 18.6

Total

47.8 ± 11.4

48.2 ± 15.3

Note Data was presented as mean ± standard deviations. ASD = autism spectrum disorder, NFL = Neurofilament light chain, NLR =
Neutrophil/lymphocyte ratio, PLR = Platelet/lymphocyte ratio, TD = typically developing children, TSP1 = Thrombospondin 1, WBC
= White blood cell.
a
The ASD group is consisted of 34 children and 9 adolescents and the TD group includes 31 children and 14 adolescents.
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Table 3. Correlation between blood biomarkers and the severity of illness among 43 children with ASD.
Social communication
score

Emotional reactivity
score

Stereotyped behavior and Total CARS score
sensorial sensitivity score

Variables

Corr. coeff. p

Corr.
coeff.

p

Corr.
coeff.

p

Corr. coeff. p

NFL (pg/mL)

–0.100

0.525

0.008

0.961

–0.377

0.013

–0.214

0.169

TSP-1 (ng/mL)

–0.080

0.609

0.070

0.657

–0.390

0.010

–0.191

0.219

Note CARS = The Childhood Autism Rating Scale, Corr. Coeff = Correlation coefficient, NFL = Neurofilament light chain,
TSP-1 = Thrombospondin-1

of both studies could stem from demographic differences
and ongoing medications. On the other hand, we did not
confirm that the severity of autism was correlated with
the serum NFL levels [21]. Yet, the age groups of both
samples represent different neurodevelopmental stages of
the brain. It might be argued that these discrepant results
might be associated with varying pruning patterns in the
brain. Accordingly, despite the modest sample size, the
results of our study suggest that the neurodegenerative
biomarker levels of ASD were similar to those of TD
during the peripubertal period and early adolescence.
Loss of previously-acquired skills (also called
“regression”) and/or structure of neurons were suggested
as the signs of neurodegeneration, which might be related
to increased proinflammatory cytokines, microglial
activation, and oxidative stress leading to a type of
progressive encephalopathy [6]. However, progressive
encephalopathy might not be the case for relatively stable
phases of ASD, or a slower rate of degeneration could remain
undetectable in plasma. In line with our findings, a recent
study did not find any difference between adult patients
with major psychiatric disorders (e.g., schizophrenia,
bipolar disorder, and major depressive disorder) and
healthy comparisons [29]. Authors concluded that similar
levels of NFL between psychiatric disorders and controls
did not support the neurodegenerative process in the course
of psychiatric disorders [29]. Likewise, another study
involving children with progressive and nonprogressive
neurological illnesses revealed NFL differentiated ongoing
neural and/or axonal damage from stationary and stable
neurologic diseases [30].
On the other hand, in the extant literature, children
with autism were shown to have normal brain volume
at birth, yielding an overgrowth in early childhood and
total brain volume reached a plateau during adolescence
within the range of typical development [31]. In addition,
it was shown that patients with ASD had a sharper decline
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in total brain volume in late adolescence and young
adulthood compared to typical development after the
ages of 10–15 years [32]. Considering the mean age of
our participants was ten years at the time of recruitment,
chronologic age might be a confounding factor for the
assessment of a neural biomarker. Besides, a preliminary
study found a plasma glial fibrillary acidic protein levels
in the ASD group were three times lower than those in
the control group, and the mean age of the study group
was approximately four years in that study [33]. Finally,
we found a positive correlation between age and NFL in
the patient group, but not in the TD children; therefore,
it might be argued that this finding could be linked to the
accelerated volumetric changes during adolescence among
the ASD population.
Plasma TSP-1 was also found similar between study
groups. As previously mentioned, TSP-1 was an essential
protein of synaptogenesis and interacted with Neuroligin 1
during synapse formation [22, 24, 34]. Although common
and rare variants of the THBS1 gene were somewhat linked
to ASD [26], it might be implicated in the early stages of
brain development. Thus, despite its role in synaptogenesis,
TSP-1 was not considered a peripheral biomarker of
ASD. Additionally, TSP-1 has several regulatory and
structural functions in the ECM, including angiogenesis,
cell adhesion, and apoptosis [23]. Therefore, TSP-1 could
be affected by pathological and physiological processes
within the ECM of peripheral tissues. Accordingly, CSF
levels of TSP-1 could indicate more conclusive results in
younger patients.
Our study results did not suggest a robust relationship
between biomarkers and the clinical characteristics of
patients. We did not find any difference between patients
receiving antipsychotic and antiepileptic medications.
Antipsychotics had some anti-inflammatory effects on the
immune system in rat models [35]. Of note, risperidone
could cause immune alterations in the course of treatment
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[36]. Yet, the protective effects of existing medications from
the neurodegenerative process are not solely concluded
by these molecular findings, since cognitive impairment,
the development of psychosis, or mood disorders could
commonly occur during the transition to adulthood in the
longitudinal follow-up [37].
There was a negative correlation between stereotypic
behavior/sensorial sensitivity symptom scores and
serum NFL and TSP-1. However, this relationship might
be indirect since stereotypic behaviors and restricted
interests were shown to be more prevalent in younger
ages in the course of ASD, which seems a confounding
factor [38]. Similarly, patients with EEG abnormalities
had higher levels of NFL; yet, these findings were not
controlled for age. Taken together, the connection between
clinical characteristics and biomarkers requires further
exploration.
The results of this study suggested white blood cell
and lymphocyte counts were higher in patients with ASD
compared to controls. In contrast to our results, a recent
study proposed patients with ASD had elevated monocyte
counts; nevertheless, lymphocytes and neutrophils were
similar to those of controls, resulting in a lower lymphocyte/
monocyte ratio in the patients with ASD [8]. However, the
mean age of the case group in this study was 13.5 years,
which could partially explain the discrepant results. Another
study also suggested a higher neutrophil/lymphocyte ratio
among the unmedicated patients with ASD than age- and
sex-adjusted controls [9]. Given the inconsistency in the
literature regarding blood cell counts, the diagnostic and
prognostic values of blood cells are still unclear. Since the
case groups of both studies did not receive any treatment,
antipsychotics and antiepileptic medications used in our
sample could alter the number of blood cells, leading to
deviations from the previous findings.
Several limitations have to be taken into consideration
to interpret the study results. First, the cross-sectional
design of the study did not endorse repeated measures
to reveal possible changes in serum levels. Yet, the mean
age of the ASD group was 10.0 years, which allows us
to find a response to the research question of whether
neurodegeneration occurs during the peripubertal periods
of patients with autism. Similarly, comorbidities and
medication use might affect study results. However, posthoc
tests suggested that medications did not have any significant

effect on serum biomarker levels. On the other hand, we
implemented correlation analyses to detect possible effects
of the severity of symptoms, age, and medications. The
diagnosis of ASD was not evaluated with a gold-standard
instrument. However, a severity threshold of CARS scores
≥ 30 only endorsed moderate or severe cases to be included.
Our sample size was also modest, especially for posthoc
analyses. Therefore, some of the posthoc analyses were
underpowered. Yet, we implemented a power analysis to
determine the required sample size. Finally, blood levels
might not reflect spinal fluid or the brain. Despite these
limitations, to the best of our knowledge, this is the first
study to compare serum TSP-1 levels between patients with
ASD and TD children. Also, our results did not confirm
elevated serum NFL levels in peripubertal patients with
ASD. Considering the growing evidence in this field, the
results of this research contributed to the current literature
on biomarkers.
In conclusion, the NFL and TSP-1 did not differ between
children with ASD and control groups. The results do not
support the neurodegenerative process of patients with
ASD during the peripubertal period. Designs with repeated
neuropsychological and neuroimaging assessments, which
could show the patterns of cognitive and functional decline,
are needed to investigate the neurodegeneration of ASD.
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